ACS chemical neuroscience molecule spotlight on Saphris.
On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously. Saphris (asenapine) is a multitarget atypical antipsychotic medication approved to treat adults with schizophrenia and bipolar I disorder.
Vanderbilt University, Vanderbilt University Medical Center Department of Pharmacology, and Vanderbilt Program in Drug Discovery, Nashville, Tennessee, USA.
Corey R
CR
Hopkins
D000286:Administration, Sublingual; D017109:Akathisia, Drug-Induced / Q000209:etiology; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001682:Biological Availability; D001714:Bipolar Disorder / Q000188:drug therapy; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015394:Molecular Structure; D017981:Receptors, Neurotransmitter / Q000037:antagonists & inhibitors; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings; D017981:Receptors, Neurotransmitter; C522667:asenapine